Japanese Health Ministry OKs Bayer's Chronic Heart Failure Treatment

03:27 AM EST, 12/22/2025 (MT Newswires) -- German biopharmaceutical group Bayer (BAYN.F) secured the Japanese Ministry of Health, Labour and Welfare's approval for its nonsteroidal, selective mineralocorticoid receptor antagonist finerenone to treat chronic heart failure. Finerenone is indicated for chronic heart failure with a left ventricular ejection fraction higher than 40%, according to a Monday release. The approval is backed by data from the phase 3 Finearts-HF study, in which finerenone demonstrated a statistically significant and clinically meaningful reduction of the composite of cardiovascular death and total heart failure events, compared with placebo.